How European RIs can boost Open Science & Open Innovation
|
|
|
- Winifred Shields
- 6 years ago
- Views:
Transcription
1 How European RIs can boost Open Science & Open Innovation Kurt Zatloukal, Medical University Graz, Austria Corbel Innovation Meeting Brussels, June 20th, 2017 Grant agreement No Funded by GZ /0016-II/3/2013
2 Research Education Research Infrastructures Innovation The quality of public research infrastructures may be one of the most important national assets for supporting innovation from National Innovation Systems, OECD 1997
3 BMS Research Infrastructures and the Health Innovation Chain Disease Biospecimens Med. data Molec. data Health Innovation Chain Knowledge Diagnostics Therapies
4 BMS Research Infrastructures and the Health Innovation Chain Disease Biospecimens Med. data Molec. data Health Innovation Chain Knowledge Diagnostics Therapies
5 BMS Research Infrastructures and the Health Innovation Chain Disease Biospecimens Med. data Molec. data Knowledge Health Innovation Chain RIs contribute: Resources Technologies Services Data/knowledge Diagnostics Therapies
6 How can BMS RIs boost Innovation? The BBMRI-ERIC Expert Center Example
7 Industry Needs Access to Biosamples Without access to biosamples essentially no insight into molecular disease mechanisms, no new biomarkers, no new drugs, no advancement of personalized medicine.
8 Nature September 2009
9 Access for Industry Common good (donations) Industry Medical data Biological samples Knowledge? Diagnostics Drugs Public (not-for-profit) Private (for-profit)
10 Expert Centres: Win-Win for Public and Private Sectors Common good (donations) Expertise Expertise Industry Funds Medical data Biological samples Knowledge Primary data generation Diagnostics Drugs Public (not-for-profit) Data Public Private pre-competitive (not-for-profit) Products IPR Private (for-profit) Standardisation of data generation Basis for data sharing Better usage of finite resources Collaborative research to improve innovation
11 (public) Expert Centres as Highways for International Research Collaborations Biological Resource Centre Samples Medical Data Expert Centre Research Data Expert Centre Samples Medical Data Biological Resource Centre Country 1 Country 2 Biological Resource Centre Samples Medical Data Expert Centre Country 3
12 (public) Expert Centres as Highways for International Research Collaborations Biological Resource Centre Samples Medical Data Expert Centre Research Data Expert Centre Samples Medical Data Biological Resource Centre Country 1 Country 2 OECD GBRCN Biological Resource Centre Samples Medical Data Expert Centre Country 3
13 BBMRI-ERIC Expert Centres Framework for collaborative research Public private partnership Platform for sharing of biological resources, data and knowledge Common QM: reference material and proficiency testing together with other ECs Building block of a global open data resource Enabler for (open)innovation
14 Research Infrastructures Innovation Expert Center Concept for Corbel: Open Data is a commmon product Open access Open access DATA KNOWLEDGE Restricted access ethnical & legal issues Top quality Ehical and legal clearance Efficient processes Restricted access IP matters
15 Open Data on the Top Agenda
16 The European Open Science Cloud Federating existing scientific data infrastructures Provide secure environment, privacy, data protection New market opportunties for health, environment, transport Provide interoperability, data services, incentives, governance All H2020 data should become open according to FAIR principle European Data Infrastructure 3.5 bio investment
17 The FAIR Principle F Findable A - Accessible I Interoperable R Reusable
18 Some Caveats
19 Underestimated Issue: Specific Features of Health Data Sensitive data (identifyable personal data) Highly regulated (GDPR, ethics, health care) Potential high value, complex ownership Heterogeneous data (plain text in national language, imaging, laboratory, life style, -omics etc.) Heterogeneous quality Data provenance, series (disease course, versioning, evolution) Complex access procedures
20 Limited Reproducibility of Scientific Data
21 A Case for Sample and Data Quality
22 Impact of Errors in Medical Diagnostics 46% - 68% of diagnostic testing process errors are in the pre-analytical phase Plebani M, Clin Chem Lab Med percent of U.S. adults experience a diagnostic error 10 percent of patient deaths can be attributed to diagnostic errors 6 to 17 percent of adverse events in hospitals are related to diagnostic errors Institute of Medicine SEPTEMBER 2015 Improving Diagnosis in Health Care The National Academy of Sciences.
23 Emerging European and ISO Standards European IVD Regulation SPIDIA CEN/TC 140 ISO/TC 212 ISO15189 Technical specifications for pre-examination processes ISO/TC 276 Biotechnology Biobanks and Bioresources Zatloukal QBB Conference 2017
24 Open Access Created the Most Valuabel Companies in the World Apple Top 10 Companies in the world 2016 Alphabet Facebook 8% 7% 16% Amazon Microsoft Exxon Mobil Berkshire Hathaway Johnson & Johnson General Electric Wells Fargo 9% 8% 9% 12% 7% 9% 15% Enabled by free access to internet
25 THANK YOU!
Innovative Technology and Its Contribution to Biobanking
Global Biobank Week Stockholm, September 13th - 15th, 2017 Innovative Technology and Its Contribution to Biobanking Kurt Zatloukal M.D. Institute of Pathology Medical University of Graz Austria Drivers
ROUND TABLE ARISLA Milano 26 marzo 2014 Le BioBanche Nodo Italiano di Biobanking and Biomolecular Resources Research Infrastructure
ROUND TABLE ARISLA Milano 26 marzo 2014 Le BioBanche Nodo Italiano di Biobanking and Biomolecular Resources Research Infrastructure Marialuisa Lavitrano Università Milano-Bicocca Coordinatore BBMRI-Italia
The Hellenic Network of Biobanks-BBMRI-GR Dr. S.Kolyva Representative of Greece in the General Assembly of BBMRI-ERIC
The Hellenic Network of Biobanks-BBMRI-GR Dr. S.Kolyva Representative of Greece in the General Assembly of BBMRI-ERIC BBMRI policies Primacy Respect the primacy of national and European legislation and
Amendment of the Work Programme 2017 version 1
AMENDMENT OF THE CORE WORK PROGRAMME 2017 Version 1.1 Prepared for the consideration of the AoM#9 11 April 2017 1 This document is concerned with amendments to the Core Work Programme 2017. It contains
IBBL: Introduction to Biobanks and their services
IBBL: Introduction to Biobanks and their services HighTech meets Health, Oss (NL), 15 th June 2017 Monica Marchese, PhD Biomarker Validation Scientist AN ACCREDITED & CERTIFIED BIOBANK INFRASTRUCTURE FOR
Leveraging an Academic-Industry Partnership for Commercial Success
Leveraging an Academic-Industry Partnership for Commercial Success For 115 Years, the Nation s Leading Respiratory Hospital Respiratory Heritage: 115 Years of Respiratory Research and Care Allergy, Asthma,
BBMRI.NL A story of Sharing Eline Slagboom Molecular Epidemiology, Leiden University Medical Center Brussel 20 Juni 2017
BBMRI.NL A story of Sharing Eline Slagboom Molecular Epidemiology, Leiden University Medical Center Brussel 20 Juni 2017 BBMRI-NL TOWARDS A NATIONAL BIOBANKING INFRASTRUCTURE Founded in 2009 as the Dutch
Adapting research to the 21st century the Swedish Biobank Register
Norsk Epidemiologi 2012; 21 (2): 149-153 149 Adapting research to the 21st century the Swedish Biobank Register L. Norlin 1, M. Fransson 1, S. Eaker 2, G. Elinder 3 and J.-E. Litton 1 1) Karolinska Institutet,
Future of the Project. BioMedBridges 3rd Annual General Meeting 18 February 2015, Munich Janet Thornton
Future of the Project BioMedBridges 3rd Annual General Meeting 18 February 2015, Munich Janet Thornton What were goals of BioMedBridges? GOAL 1: To provide computational data and service bridges between
Personalized. Health in Canada
Personalized Health in Canada Canadian Institutes of Health Research Personalized Medicine Signature Initiative 2010-2013 0 Dr. Morag Park CIHR Institute of Cancer Research Dr. Paul Lasko CIHR Institute
Nordic Register and Biobank Data
Nordic Register and Biobank Data A basis for innovative research on health and welfare Juni Palmgren Karolinska Institutet, Stockholm Nordic conference on Real World Data Helsinki November 2016 Nordic
Rare Diseases: Challenges and Opportunities NIH Perspective
Rare Diseases: Challenges and Opportunities NIH Perspective Stephen C. Groft, Pharm.D. Office of Rare Diseases Research (ORDR) National Center for Advancing Translational Science (NCATS) National Institutes
"Stratification biomarkers in personalised medicine"
1/12 2/12 SUMMARY REPORT "Stratification biomarkers in personalised medicine" Workshop to clarify the scope for stratification biomarkers and to identify bottlenecks in the discovery and the use of such
GENERAL PAYER CONSIDERATIONS FOR NEW HEALTH TECHNOLOGIES (INCLUDING DIAGNOSTICS)
FORUM Payer perspectives and actions impacting diagnostics in the US and Europe Eric Faulkner, MPH Director, Quintiles Global Market Access Consulting; Executive Director, Genomics Biotech Emerging Medical
The European Commission s science and knowledge service
The European Commission s science and knowledge service Joint Research Centre European Platform on Rare Diseases Registration Andri Papadopoulou Simona Martin Agnieszka Kinsner-Ovaskainen Monica Lanzoni
European Molecular Biology Laboratory s position paper on the interim evaluation of Horizon 2020
European Molecular Biology Laboratory s position paper on the interim evaluation of Horizon 2020 I. Introduction role of EMBL in life science research in Europe The European Molecular Biology Laboratory
TOTAL CANCER CARE: CREATING PARTNERSHIPS TO ADDRESS PATIENT NEEDS
TOTAL CANCER CARE: CREATING PARTNERSHIPS TO ADDRESS PATIENT NEEDS William S. Dalton, PhD, MD CEO, M2Gen & Director, Personalized Medicine Institute, Moffitt Cancer Center JULY 15, 2013 MOFFITT CANCER CENTER
Roche in Australia Innovation Leader
Roche in Australia Innovation Leader About Roche Innovation: it s in our DNA 7,000,874 hours of work 6,587 experiments 423 researchers 1 drug For nearly 120 years, Roche has been committed to improving
Type of Activity. Universal Activity Number L04-P
Below are the pharmacy designated Universal Activity Numbers (UANs) and type of activity that is applicable for each of the following program offerings Session # Title 104 Impact of Biologics, Vaccines,
NHS ENGLAND BOARD PAPER
NHS ENGLAND BOARD PAPER Paper: PB.30.03.2017/06 Title: Creating a genomic medicine service to lay the foundations to deliver personalised interventions and treatments Lead Director: Professor Sir Bruce
The Lifecycle of a Sample
The Lifecycle of a Sample Samples are the basis by which all research decisions are made. By following best practices in data management, it is possible to optimise collections, minimise the effect of
IVD Regulation 2017/746
IVD Regulation 2017/746 Dr. Anne Van Nerom Famhp 2017-06-13 Recast-symposium Auditorium Storck (Eurostation II) Rue Juliette Wytsmanstraat 14 1050 Brussels Belgium T +32 2 642 51 11 F +32 2 642 50 01 email:
Bridging the Gap Between Basic and Clinical Research. Julio E. Celis Danish Cancer Society
Bridging the Gap Between Basic and Clinical Research Julio E. Celis Danish Cancer Society Barriers and Oportunities in Translational Research Promise of the new technologies What is Europe doing? Challenges
Comments from the FDA Working Group on SUBGROUP ANALYSES. Estelle Russek-Cohen, Ph.D. U.S. Food and Drug Administration Center for Biologics
Comments from the FDA Working Group on SUBGROUP ANALYSES Estelle Russek-Cohen, Ph.D. U.S. Food and Drug Administration Center for Biologics 1 Outline An intro to FDA EMA and FDA on subgroups Companion
Reduce costs of the early drug development process Increase probality of developing drugs that enter late clinical phases
Aktivitetsplan 5 - Application for Strategic collaboration on joint development and implementation of service offerings between Bioneer A/S and Fraunhofer Institute for Biomedical Engineering (Særskilt
OPINIONS. A Troponin Assay Conversion: What Success Looks Like WHAT MAKES TROPONIN ASSAYS DIFFERENT FROM ONE ANOTHER? ...
SC A Troponin Assay Conversion: What Success Looks Like Brad P. Mayeux 1 * Cardiac troponin (ctn) 2 assays have been available to the medical community for over 20 years for the aid in diagnosis, risk
Section I: Pharmaceuticals and Medical Devices
SUPPLEMENT on HEALTHCARE INNOVATION Visionary Goals and Recommendations 51th Japan-U.S. Business Conference Japan-U.S. Business Council / U.S.-Japan Business Council November 14, 2014 The R&D-based pharmaceutical
Plataformas de apoyo a la investigación: biobancos y centros de recursos biológicos
Plataformas de apoyo a la investigación: biobancos y centros de recursos biológicos Jornadas: La realidad de los biobancos a la luz del nuevo marco normativo: retos e implicaciones Centro de Investigación
Molecular Diagnostics
Molecular Diagnostics Part II: Regulations, Markets & Companies By Prof. K. K. Jain MD, FRACS, FFPM Jain PharmaBiotech Basel, Switzerland May 2018 A Jain PharmaBiotech Report A U T H O R ' S B I O G R
International standard for Biobanking
International standard for Biobanking Georges Dagher Inserm, BBMRI Paris, France 20/10/2017 GBW meeting 1 Increase quality Decrease Cost Take home message 20/10/2017 GBW meeting 2 Most of our current knowledge
EIS Implementation Review ISA Coordination group meeting
JOINING UP GOVERNMENTS EUROPEAN COMMISSION EIS Implementation Review ISA Coordination group meeting 23 October 2012 EIS Implementation review Context The EIS Implementation Review aims at guaranteeing
EU support for Health Research from FP6 to FP7
EU support for Health Research from FP6 to FP7 Stéphane Hogan Head of Biotechnology Unit Directorate for Health Research DG Research - European Commission Valencia - 15 September 2006 EU research programmes
Delivering on the promise: the clinical application of new diagnoses and treatments for RD K A T E B U S H B Y N E W C A S T L E U N I V E R S I T Y
Delivering on the promise: the clinical application of new diagnoses and treatments for RD K A T E B U S H B Y N E W C A S T L E U N I V E R S I T Y PERSPECTIVE/ DISCLAIMERS Doctor with >24 years experience
Institute of Internal Auditors 2018 IIA CHICAGO CHAPTER JOIN
IIA CHICAGO CHAPTER JOIN US: @IIACHI CURIOUS AND EVER CHANGING DOMINIQUE VINCENTI / NORDSTROM APRIL 9, 2018 A case for never suffering transformation but leading change at all times. IIA CHICAGO CHAPTER
Università Cattolica del Sacro Cuore
Università Cattolica del Sacro Cuore The role of Regulatory Affairs in drug development Francesco Mazza, Director of Legal, Fiscal & Compliance Affairs in Farmindustria Rome, May 12 2017 Who we are Who
Director Healthcare Biotech
Director Healthcare Biotech EuropaBio, the European Association for Bioindustries, promotes an innovative and dynamic European biotechnology industry. EuropaBio and its members are committed to the socially
WP8 Status update. Henrik Edgren on behalf of WP8 (EBI, KI, UDUS, TUM-MED, UH) First BioMedBridges Annual General Meeting March 2013, Düsseldorf
WP8 Status update Henrik Edgren on behalf of WP8 (EBI, KI, UDUS, TUM-MED, UH) First BioMedBridges Annual General Meeting 11-12 March 2013, Düsseldorf PM use case The PM project is a collaboration between
Personalised Healthcare Solutions (PHCS) Excellence for your Biomarker-driven Strategies
Personalised Healthcare Solutions (PHCS) Excellence for your Biomarker-driven Strategies The value of In Vitro Diagnostics The value of diagnostics as an integral part in the healthcare value chain Diagnostics
Roche, Roche Molecular Diagnostics and more
, Molecular and more [Monte Wetzel, PhD] Patients have questions. We provide answers. Group Clear focus on Healthcare Innovation with two strong pillars Pharma Pharma Genentech Chugai Molecular Professional
Update on Regulatory Environment- Europe Experience with 2007/47/EC M5 & Discussions on Possible Recast of EU Medical Device Regulations
Update on Regulatory Environment- Europe Experience with 2007/47/EC M5 & Discussions on Possible Recast of EU Medical Device Regulations Paul Brooks Vice President Healthcare, Americas Presentation to:
The world of GS1 standards in healthcare. Chris Adcock GS1 Global Office
The world of GS1 standards in healthcare Chris Adcock GS1 Global Office Topics Background Where we are going Where we are today What this means to you Questions Background Topics Where we are going Where
The 100,000 Genomes Project Genomics Collaboration Event Finnish Residence
The 100,000 Genomes Project Genomics Collaboration Event Finnish Residence Prof Mark Caulfield FMedSci Chief Scientist for Genomics England Barts Heart Centre William Harvey Research Institute Queen Mary
Molecular Diagnostics for Global Heath Problems. Proactive Investors Forum 5 October 2017
Molecular Diagnostics for Global Heath Problems Proactive Investors Forum 5 October 2017 2 Document Information The information contained in this document and made verbally to you (together the Presentation
Platform Thinking & Fintech programme for Banks, Financial institutions and Digital Companies. PwC s Academy
Platform Thinking & Fintech programme for Banks, Financial institutions and Digital Companies PwC s Academy FinTech and disruptive entities E-retailers are likely to be disruptive by using their large
Data Sources and Biobanks in the Asia-Pacific Region. Wei Zhou, MD, Ph.D. Department of Epidemiology, Merck Research Laboratories October 23, 2014
Data Sources and Biobanks in the Asia-Pacific Region Wei Zhou, MD, Ph.D. Department of Epidemiology, Merck Research Laboratories October 23, 2014 1 Disclosures Wei Zhou is currently an employee of Merck
Siemens Healthineers presents solutions for the digitalization in healthcare
Press Erlangen, April 24, 2017 ConhIT 2017, Berlin, April 25 th to 27 th, 2017, in hall 2.2, no. B 112 presents solutions for the digitalization in healthcare New partners for the Digital Ecosystem: Ebit
The Yale Open Data Access (YODA) Project: Lessons Learned in Data Sharing
The Yale Open Data Access (YODA) Project: Lessons Learned in Data Sharing Grand Rounds: A Shared Forum of the NIH HCS Collaboratory and PCORnet June 30, 2017 Joseph S. Ross, MD, MHS Section of General
First Annual Biomarker Symposium Quest Diagnostics Clinical Trials
First Annual Biomarker Symposium Quest Diagnostics Clinical Trials Terry Robins, Ph.D. Director Biomarker R&D and Scientific Affairs Quest Diagnostics Clinical Trials Key Considerations: Biomarker Development
European Data Economy
CER position Brussels, 26 April 2017 1 CER aisbl - COMMUNITY OF EUROPEAN RAILWAY AND INFRASTRUCTURE COMPANIES Avenue des Arts, 53-1000 Bruxelles T: +32 (0)2 213 08 70 F: +32 (0)2 512 52 31 @CER_railways
Standards of proficiency. Biomedical scientists
Standards of proficiency Biomedical scientists Contents Foreword 1 Introduction 3 Standards of proficiency 7 Foreword We are pleased to present the Health and Care Professions Council s standards of proficiency
European Induced Pluripotent Stem Cell Bank
European Induced Pluripotent Stem Cell Bank Background Researchers are looking for ways to validate pathways using human data. ips cells are one approach to this. ips research and banking is fragmented
Use of Big Data to Support Regulatory Decision Making
Use of Big Data to Support Regulatory Decision Making EMA-EuropaBio Annual Bilateral meeting Dr Alison Cave, Principal Scientific Administrator, Pharmacovigilance and Epidemiology Department An agency
Innovating out of Crisis
Innovating out of Crisis Shigetaka Komori Chairman and CEO FUJIFILM Holdings Corporation 1 st June, 2015 Business Fields of Fujifilm Group Digital Camera Photo book Optical devise FY2015/3 Digital minilab
The In Vitro Diagnostic CRO
The In Vitro Diagnostic CRO Choose Beaufort Because of Our People, Processes and Proven Experience The value of expertise cannot be overstated, especially when it comes to streamlining complicated in vitro
BIOCRATES Life Sciences AG Short Company Presentation
BIOCRATES Life Sciences AG Short Company Presentation Dr. Alexandra C. Gruber MBA MMFin Director Business Development / Marketing Austria Showcase Life Science Japan, Tokyo, December 2010 BIOCRATES Life
Preanalytical Processing: The Biospecimen Quality Imperative
Preanalytical Processing: The Biospecimen Quality Imperative Carolyn Compton, MD, PhD Chair, Scientific Advisory Committee, Indivumed GmbH Professor of Life Sciences, ASU Professor of Laboratory Medicine
European Union Network Data Board Terms of Reference
10 January 2018 EMA/231985/2016 Terms of Reference 1. Remit, vision and mission The (EUNDB) is an advisory body co-chaired by the Head of Business Data and Support Department (EMA) and a National Competent
CURRENT ISSUES IN INTELLECTUAL PROPERTY: A PATIENT PERSPECTIVE
CURRENT ISSUES IN INTELLECTUAL PROPERTY: A PATIENT PERSPECTIVE Consumer Advocare Network s submission to WHO's Second Public Hearing on Public Health Innovation and Intellectual Property The Consumer Advocare
Participative Innovation for Collaborative Society
Participative Innovation for Collaborative Society Open Service Innovation; Bror Salmelin Advisor to the Director bror.salmelin@ec.europa.eu Innovation? Make things happen! User-centric innovation Open
Canadian Longitudinal Study on Aging (CLSA) Data and Biospecimen Access Policy and Guiding Principles
Canadian Longitudinal Study on Aging (CLSA) Data and Biospecimen Access Policy and Guiding Principles CLSA_DataBiospecimenPolicy v2.0 2018Mar16 Page 1 of 7 1.0. DEFINITIONS 1.1. Applicant: an investigator
Nordic Biobank Collaboration Opportunities and Obstacles. Joakim Dillner Director, BBMRI.se (Sweden)
Nordic Biobank Collaboration Opportunities and Obstacles Joakim Dillner Director, BBMRI.se (Sweden) What is the Nordic advantage, really? -Possibility to link biobanks to nationwide, comprehensive registries
Webinar IMI2 Call 14 Opportunities for SMEs
Webinar IMI2 Call 14 Opportunities for SMEs 19 March 2018 Agenda How to use GoToWebinar Catherine Brett, IMI Opportunities for SMEs Colm Carroll, IMI Questions & answers How to use GoToWebinar - audio
FDA Regulation of In Vitro Diagnostics: Current Perspectives and Initiatives
FDA Regulation of In Vitro Diagnostics: Current Perspectives and Initiatives Katherine Donigan, Ph.D. Office of In Vitro Diagnostics and Radiological Health, FDA Life Science Tennessee Annual Conference
MAYO CLINIC CENTER FOR BIOMEDICAL DISCOVERY EXCEPTIONAL RESEARCH LEADS TO EXCEPTIONAL PATIENT CARE
MAYO CLINIC CENTER FOR BIOMEDICAL DISCOVERY EXCEPTIONAL RESEARCH LEADS TO EXCEPTIONAL PATIENT CARE THE RESEARCH WE DO TODAY WILL DETERMINE THE TYPE OF MEDICAL AND SURGICAL PRACTICE WE CARRY ON AT THE CLINIC
Actual developments in normative regulations for Biological Resource Centers - the ISO initiatives on Biotechnology and Biorisk Management
Actual developments in normative regulations for Biological Resource Centers - the ISO initiatives on Biotechnology and Biorisk Management ECCO XXXIV European Culture Collections as tools in research and
FUJITSU Transformational Application Managed Services
FUJITSU Application Managed Services Going digital What does it mean for Applications Management? Most public and private sector enterprises recognize that going digital will drive business agility and
ASIAN PATENT ATTORNEYS ASSOCIATION Recognized Group of Korea. Report to Emerging IP Rights Committee 2012, Chiang Mai
ASIAN PATENT ATTORNEYS ASSOCIATION Recognized Group of Korea Report to Emerging IP Rights Committee 2012, Chiang Mai SPECIAL TOPIC REPORT ON Business Methods and the Laws of Nature, As Discussed by the
CENTRAL NERVOUS SYSTEM (CNS) BIOMARKERS: TECHNOLOGIES AND GLOBAL MARKETS
CENTRAL NERVOUS SYSTEM (CNS) : TECHNOLOGIES AND GLOBAL MARKETS BIO074C March 2016 Jackson Highsmith Project Analyst ISBN: 1-62296-246-X BCC Research 49 Walnut Park, Building 2 Wellesley, MA 02481 USA 866-285-7215
Global In-Vitro Diagnostics (IVD) Market Report
Global In-Vitro Diagnostics (IVD) Market Report ----------------------------------------- 215 Executive Summary The diagnostic industry is widely classified into two types: In-vitro diagnostics and In-vivo
SAMBIO Core Facilities at the University of Gothenburg
SAMBIO Core Facilities at the University of Gothenburg 1(7) Scientific Background Health care in a global perspective is much recognized as a matter of inequity among different populations around the world
Question 1: Better codification and classification of RD Yes, we agree. Question 2: Establishment of an inventory of RD Yes I agree.
Question 1: Is the current EU definition of a rare disease satisfactory? Better codification and classification of RD: The EU should cooperate closely with WHO in the process of revising the existing ICD
The European Research Council. CRISPR-Cas9 research in ERCEA Ethics Process. Filipa Ferraz de Oliveira ERCEA Scientific Officer
The European Research Council CRISPR-Cas9 research in ERCEA Ethics Process Filipa Ferraz de Oliveira ERCEA Scientific Officer Fostering Responsible Research With CRISPR-Cas9, Paris, March 2016 1 CRISPR-Cas9
Industry Academic Collaboration: A Key to Successful Involvement of Patients Early in Clinical Development
Industry Academic Collaboration: A Key to Successful Involvement of Patients Early in Clinical Development Aernout van Haarst PhD Director, European Corporate Development Feb 2016 Industry Academic Collaboration
Centricity 360 Suite Case Exchange Physician Access Patient Access
Centricity 360 Suite Case Exchange Physician Access Patient Access Unleash the power of GE collaboration solutions to bring your distributed care teams together. Centricity 360 Suite with Case Exchange,
Virginia s Health Competencies for Direct Support Professionals and Supervisors who support individuals with Developmental Disabilities
Health Competencies Checklist (rev. 6.10.16) Virginia s Health Competencies for Direct Support Professionals and Supervisors who support individuals with Developmental Disabilities The Direct Support Professional
Harmonization: why you should care!
Harmonization: why you should care! Greg Miller, PhD, DABCC Virginia Commonwealth University Richmond, Virginia gmiller@vcu.edu University of Utah, ARUP, April 20, 2017 Financial disclosures Siemens Healthcare
Perspective: Convergence of CLIA and FDA Requirements A Rational Shift in the Regulatory Paradigm
Perspective: Convergence of CLIA and FDA Requirements A Rational Shift in the Regulatory Paradigm Planning for Efficiencies of Data, Resources, and Timelines A PRECISION BRIEF Introduction As precision
Molecular Diagnostics at the Point of Need
Molecular Diagnostics at the Point of Need 24 November 2016 David Budd CEO d.budd@genedrive.com 1 DOCUMENT INFORMATION The information contained in this document and made verbally to you (together the
Pharmacovigilance & Signal Detection
Pharmacovigilance & Signal Detection 30 th International Conference on Pharmacoepidemiology & Therapeutic Risk Management Pre-conference educational session Thursday, October 23, 2014; 2:00-6:00pm Semi-automated,
For personal use only
Shareholder Presentation Perth, WA Annual General Meeting 17th November 2016 Global leader in applying proteomics to MedTech ASX: PIQ 1 Disclaimer & forward-looking statements This Presentation is provided
11% of employees are dedicated to R&D. 11 billions IVD market size 3,000 companies 75,000 people employed. 40,000 IVD products
About edma EDMA The European Diagnostic Manufacturers Association is an international, non-profit organisation representing the interests of the European in vitro diagnostics industry at the European and
ISO INTERNATIONAL STANDARD. Health informatics Requirements for an electronic health record architecture
INTERNATIONAL STANDARD ISO 18308 First edition 2011-04-15 Health informatics Requirements for an electronic health record architecture Informatique de santé Exigences relatives à une architecture de l'enregistrement
Trans-omics for a better life
Trans-omics for a better life History From 1% to World Leading The largest genomic organization in the world Focus on research and applications in the healthcare, agriculture, conservation, and environmental
Investments in the Life Sciences
Investments in the Life Sciences where how why June 4 th, 2014 Horst Domdey History of the Munich Biotech Cluster 1984 Foundation of the Munich Gene Center 1989 1 st Munich biotech company 1996 Munich
Real World Data Pilotprosjekt mellom LMI og Kreftregisteret; hvilken nytte kan industri og myndigheter ha av dette?
Real World Data Pilotprosjekt mellom LMI og Kreftregisteret; hvilken nytte kan industri og myndigheter ha av dette? November 2017 Steinar Thoresen Abbvie Disclosure 2013- Medical Director AbbVie Norway
Anne-Grete Ellingsen, CEO GCE NODE
Anne-Grete Ellingsen, CEO GCE NODE The Norwegian cluster program Collaboration on competence building and innovation Stronger interaction and collaboration Common strategic focus Increased innovation and
Nanotechnology and Advanced Materials for more effective Healthcare
Nanotechnology and Advanced Materials for more effective Healthcare This challenge taps into the potential of nanotechnologies and advanced materials to enable more effective therapies and diagnostics
Health Systems Engineering Call to action
Health Systems Engineering Call to action APICS DC Metro Chapter Presenters: Satish Gattadahalli and Bill Barton Date: July 21, 2015 Property of Whitney, Bradley & Brown, Inc. 2012. WBB s practices for
Stem Cells: Ethics and Oversight May 24, Sidney H. Golub, Ph.D. Interim Director Sue & Bill Gross Stem Cell Research Center
Stem Cells: Ethics and Oversight May 24, 2017 Sidney H. Golub, Ph.D. Interim Director Sue & Bill Gross Stem Cell Research Center Nobel Laureates 2012 John Gurdon Shinya Yamanaka Pluripotent Stem Cell PLURIPOTENT
Myeloma UK Policy Working with the Pharmaceutical Industry
Policy Working with the Pharmaceutical Industry Background The relationship between patient organisations and the pharmaceutical industry has come under increasing scrutiny in recent times, with the media
The future of PMS in Healthcare IT: Announcing the cooperation with Epic. Stan Smits CEO Medical IT Philips Medical Systems
The future of PMS in Healthcare IT: Announcing the cooperation with Epic Stan Smits CEO Medical IT Philips Agenda Healthcare IT: business rationale Why Epic? Scope of the cooperation agreement Company
the EU framework programme for research and innovation
High Performance Computing First Horizon 2020 Calls (2014-2015) Dr Panagiotis Tsarchopoulos Future and Emerging Technologies DG CONNECT European Commission the EU framework programme for research and innovation
Protection of Research Participants: The IRB Process and the Winds of Change
Protection of Research Participants: The IRB Process and the Winds of Change Ethics in Patient-Oriented Research October 12, 2011 Sharon Friend Director, OHRPP Overview Charge and Function of the IRB Quick
IT Service Desk Team Leader Apprentice Job Description
IT Service Desk Team Leader Apprentice Job Description GRADE: 0-6 Months at 20122.20pa 6-18 Months at 21559.50pa 22128pa on completion of qualification HOURS 37.5 REPORTS TO & RESPONSIBLE TO: IT Service
To the President of the House of Representatives P.O. Box EA THE HAGUE. Date 19 January 2017 Progress of open science
>Return address P.O. Box 16375 2500 BJ The Hague To the President of the House of Representatives P.O. Box 20018 2500 EA THE HAGUE Research and Science Policy Rijnstraat 50 The Hague P.O. Box 16375 2500
Grand Challenges: Research infrastructures at the forefront
Translational Research and Clinical Trials Grand Challenges: Research infrastructures at the forefront ICRI Copenhagen 2012 Prof. Dr. Liselotte Højgaard, MD DMSc Chair EMRC, The European Medical research